2De Zeeuw D,Remuzzi G,Parving HH,et al.Albuminuria atherapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy[J].Circulation,2004,110(8):921-927.
3Stojiljkovic L,Behnia R.Role of rennin angiotensin system inhibitors in cardiovascular and renal protection:a lesson from clinical trials[J].Curr Pharm Des,2007,13(13):1335-1345.
4Okada S,Sato K,Higuchi T,et al.Influence of prostagI and in E1 on heavy proteinuria in slightly azotaemic diabetics[J].J Int Med Res,1991,19(2):171-173.
2Balakumar P, Arora M K, Reddy J, et al. Pathophysiology of di- abetic nephropathy: involvement of multifaceted signalling mecha- nism [ J ]. Journal of cardiovascular pharmacology, 2009, 54 (2) : 129 - 138.
3Reidy K, Kang HM, Hostetter T, et al. Molecular mechanisms of diabetic kidney disease[J]. J Clin Invest, 2014,124(6):2333-2340.
4Wang H, Deng JL, Yue J, et al. Prostaglandin E1 for preventing the progression of diabetic kidney disease[J]. Cochrane Database Syst Rev, 2010,(5):CD006872.
5Nixon RM, Muller E, Lowy A, et al. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach[J]. Int J Clin Pract, 2009,63(5):766-775.
6Siragy HM. Comparing angiotensin II receptor blockers on benefits beyond blood pressure[J]. Adv Ther, 2010,27(5):257-284.
7Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium[J]? Diabetologia, 2008,51(5):714-725.
8Christou GA,Kiortsis DN. The role of adiponectin in renal physiology and development of albuminuria[J]. J Endocrinol, 2014,221(2):R49-R61.
9Kreutz RP, Nystrom P, Kreutz Y, et al. Inhibition of platelet aggregation by prostaglandin E1(PGE1)in diabetic patients during therapy with clopidogrel and aspirin[J]. Platelets, 2013,24(2):145-150.
10Natsume T, Iwatsuki K, Nishizuka T, et al. Prostaglandin E1 alleviates neuropathic pain and neural dysfunction from entrapment neuropathy associated with diabetes mellitus[J]. Microsurgery, 2014,34(7):568-575.
